VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data for its novel BiTAC-ADC technology platform, demonstrating the ability to distinguish between breast cancer and healthy cells and achieve dose-dependent killing of 3D tumor cell spheroids. The platform is designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents, using separately delivered, systemically inactive precursor components to minimize toxicity.
The company reported that BiTAC-ADCs showed selective cytotoxicity against cancer cells while sparing healthy cells, a critical advancement in reducing side effects common with traditional chemotherapy. The data further validates the BiTAC-ADC platform and complements VERAXA's BiTAC-TCE technology, giving the company two differentiated platforms potentially applicable across multiple solid tumor indications.
Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026. The full press release is available at https://ibn.fm/QiPhH.
VERAXA Biotech AG is building a premier engine for discovering and developing next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company was founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL) and advances its pipeline using quality-by-design principles. More information and updates on VRXA can be found in the company's newsroom at https://ibn.fm/VRXA.
This announcement is significant because it demonstrates progress in VERAXA's platform technology, which could lead to more effective and safer cancer treatments. The proof-of-concept data supports the potential of BiTAC-ADCs to address a key challenge in oncology: delivering potent therapy directly to tumors while sparing healthy tissue. With two platforms now validated, VERAXA is well-positioned to attract partners and advance its pipeline toward clinical development.
Forward-looking statements in this article involve risks and uncertainties, including those detailed in the company's SEC filings. The company undertakes no duty to update this information unless required by law.
